Biotechnology Research ·
BioCellgraft is a pioneering oral healthcare focused development and commercialization company driven by experienced dental experts and educators aimed at revolutionizing oral healthcare through groundbreaking regenerative therapies. BioCellgraft represents the epitome of innovation in oral healthcare, catering to unmet needs within the dental landscape. Our focus lies in the development and delivery of regenerative treatments that enhance both soft and hard tissues in the oral cavity. Leveraging the Human Connective Tissue Matrix (HCTM), our suite of products introduces novel possibilities in tissue regeneration. In partnership with Celularity, Inc. a publicly traded (NASDAQ) company under symbol CELU BioCellgraft exclusively licensed both the patents of as well as the use of their proprietary placental derived human connective tissue matrix, Interfyl for all the areas of application involving oral maxillofacial applications inclusive of aesthetics.